{"id":3854,"date":"2022-11-01T10:03:32","date_gmt":"2022-11-01T00:03:32","guid":{"rendered":"\/eu-uk\/?p=3854"},"modified":"2022-11-01T10:06:28","modified_gmt":"2022-11-01T00:06:28","slug":"remplir-gains-australian-reimbursement","status":"publish","type":"post","link":"\/eu-uk\/blog\/2022\/11\/01\/remplir-gains-australian-reimbursement\/","title":{"rendered":"Remplir\u2122 Gains Australian Reimbursement"},"content":{"rendered":"

Orthocell\u2019s breakthrough product for peripheral nerve repair, Remplir\u2122, has now gained Australian reimbursement –\u00a0 inclusion on the Australian Prostheses List – which is an important step in providing efficient and affordable access to this device.<\/p>\n

Remplir\u2122 was recently cleared for use in Australia by the TGA and an exclusive AU\/NZ distributor appointed, Device Technologies. <\/a><\/p>\n

Australia represents a significant addressable market, with 11,780 surgical repairs of peripheral nerves completed in the 2019\/20 financial year, and Orthocell is now ideally positioned to expand its reach into the US, the largest global healthcare market in the world.<\/p>\n

Click here to read today\u2019s ASX release.<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Orthocell was featured in the widely read column, Dr Boreham\u2019s Crucible, written by respected small cap analyst and business journalist, Tim Boreham.\u00a0<\/p>\n","protected":false},"author":2,"featured_media":3857,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-3854","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-media"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t